Proposed NCD May Give Thoratec An Edge Over HeartWare
This article was originally published in The Gray Sheet
You may also be interested in...
Research Briefs: HeartWare Adds Patients To ENDURANCE; GlySure ICU Glucose Trial; Biotronik Home Monitoring
FDA has approved HeartWare’s plan to add more patients to the ENDURANCE trial of its HVAD ventricular assist device as a destination therapy for patients with end-stage heart failure. Results of a pilot trial of GlySure’s continuous glucose monitoring system were presented at a conference in South Africa. More research.
HeartWare Touts Early Success In U.S. Launch Of HVAD
HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.